Hepatopathy-Thrombocytopenia Syndrome During Actinomycin D Treatment May Be Related to MDR1 (ABCB1) Gene Polymorphisms

Başbınar Y., Amirfallah A., Çalıbaşı Koçal G., Olgun N.

AMERICAN JOURNAL OF THERAPEUTICS, cilt.23, sa.2, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1097/mjt.0000000000000020
  • Dergi Adı: AMERICAN JOURNAL OF THERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: actinomycin D, Wilms tumor, MDR1, ABCB1, hepatopathy-thrombocytopenia syndrome, CHILDHOOD
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

The antitumor agent actinomycin D has been used in the treatment of Wilms tumor for the past 40 years. Actinomycin D-induced hepatopathy-thrombocytopenia syndrome (HTS) is characterized as a rare syndrome. The mechanism underlying HTS may differ with individual multidrug resistance protein-1 (MDR1) genotype. The relationship between actinomycin D-related HTS and MDR1 gene mutations is presented in this case study of a pediatric patient with Wilms tumor. Our findings revealed that the girl had (-)1G>A, 1236C>T, 2677G>T, 3435C>T, and 61A>G MDR1 gene mutations. Understanding the function of genetic variants of MDR1 is an important aim for personalized cancer management.